Status:

COMPLETED

Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass

Lead Sponsor:

University of Sao Paulo

Conditions:

Cardiopulmonary Bypass Surgery

Aortic Valve Surgery

Eligibility:

All Genders

20-60 years

Phase:

PHASE2

Brief Summary

Introduction: Fluid overload and systemic inflammation are major contributors to postoperative complications in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Objective: To eva...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of cardiac disease requiring surgery with cardiopulmonary bypass (CPB)
  • Age ≥ 18 years
  • Ability to provide informed consent

Exclusion

  • Chronic renal failure
  • Recent cardiac catheterization within the past month
  • Planned cardiac surgeries with an estimated CPB time of less than 60 minutes
  • Aortic surgery
  • Significantly impaired hepatic function

Key Trial Info

Start Date :

April 12 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 16 2024

Estimated Enrollment :

124 Patients enrolled

Trial Details

Trial ID

NCT07212842

Start Date

April 12 2021

End Date

March 16 2024

Last Update

October 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of São Paulo Medical School in Ribeirão Preto

Ribeirão Preto, São Paulo, Brazil, 14049-900

Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass | DecenTrialz